In the preclinical trials of the H1:CAF01 vaccine, it has been demonstrated that CAF01 adjuvant significantly enhances IFN-γ production and elicits Th17-dependent memory, resulting in protection against MTB, regardless of whether it is administered before or after infection. This evidence concerns the gene IFNG and infection.